Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.8800 (1.91%) ($5.8800 - $5.8800) on Fri. Feb. 19, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.49% (three month average) | RSI | 53 | Latest Price | $5.8800(1.91%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -1% a day on average for past five trading days. | Weekly Trend | ADMS declines -0.7% a week on average for past two weeks. | Market Behavior | Rotation from growth to value for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) FXI(13%) MCHI(9%) TLT(7%) VXX(7%) VWO(6%) | Factors Impacting ADMS price | ADMS will decline at least -2.245% in a week (0% probabilities). JETS(-25%) VCSH(-23%) CEMB(-19%) REMX(-15%) XLY(-14%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.245% (StdDev 4.49%) | Hourly BBV | 0.3 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $5.89(-0.17%) | 10 Day Moving Average | $6.02(-2.33%) | 20 Day Moving Average | $5.83(0.86%) | To recent high | -11.7% | To recent low | 17.6% | Market Cap | $166m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |